Ozempic vs Trulicity
Side-by-side cost comparison based on Medicare Part D data
Ozempic
Semaglutide
Manufactured by Novo Nordisk
Trulicity
Dulaglutide
Manufactured by Eli Lilly
Trulicity costs 31% less per claim than Ozempic ($473.00 vs $685.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Ozempic | Trulicity |
|---|---|---|
| Avg Cost Per Claim | $685.00 | $473.00 |
| Total Medicare Spending | $5.0B | $4.2B |
| Total Beneficiaries | 1,180,000 | 985,000 |
| Total Claims | 7,240,000 | 8,920,000 |
| Annual Cost/Patient | $4,200.00 | $4,279.00 |
| Year-over-Year Change | +72.5% | -4.8% |
| Generic Available | No | No |
| Patent Expiration | Sep 20, 2031 | Sep 18, 2027 |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Condition | Diabetes | Diabetes |
| Generic Name | Semaglutide | Dulaglutide |
Ozempic vs Trulicity: What the Data Shows
Ozempic (Semaglutide) and Trulicity (Dulaglutide) are both used to treat diabetes. Based on Medicare Part D data, Trulicity costs $473.00 per claim, which is 31% less than Ozempic at $685.00 per claim.
Medicare spent $5.0B on Ozempic and $4.2B on Trulicity. In terms of patient reach, Ozempic serves more beneficiaries (1,180,000 vs 985,000).
Year-over-year spending changed +72.5% for Ozempic and -4.8% for Trulicity. Ozempic saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Ozempic patent expires Sep 20, 2031. Trulicity patent expires Sep 18, 2027.
Frequently Asked Questions
Trulicity is cheaper at $473.00 per claim, compared to $685.00 for Ozempic. That makes Trulicity about 31% less expensive per claim based on Medicare Part D data.
Yes, both Ozempic and Trulicity are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Ozempic patent expires Sep 20, 2031. Trulicity patent expires Sep 18, 2027.
Medicare Part D spent $5.0B on Ozempic covering 1,180,000 beneficiaries, and $4.2B on Trulicity covering 985,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
Comparing Ozempic and Trulicity on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.